RDW and Kristina have reached the point of no return!!!!Here's a small sample of their never-ending corporate malfeacance, involving one called BENCRO:
BENCRO's PRIVATE MESSAGES TO NEWDAYDAWNING
From: bencro
Date: 2/24/2018 11:43:10 AM
Subject: TLC-900 and the neurology market ...
***** FYI. Please keep this confidential. DO NOT SHARE as I want to protect this priviledged
contact ********
Got this answer, from David Smith - VP Sales:
Yes, that was certainly a good study that we’ve used to highlight this additional benefit associated with
LLLT. Just also completed a 4-probe TLC-2000 system sale to a chiro neurologist in Sonoma CA who
had been using the TLC-1000 for the past few years and moved up to the 2000 because of the additional
features and benefits. He lectures on the west coast (very popular speaker), and we will be working
closely with his clinic to conduct additional studies to support this application.
regarding this email that I sent him:
Very interesting Oct. 2017 study that uses your TLC-900 for a new market (neurology) with pretty
impressive results, on patients with different profiles and different neulogical conditions. That's a big
market. Congrats.
Management of Post-Traumatic Stress (PTSD) Dementia and Other Neuro-Degenerative Disease with
Photo-Medicine: Clinical Experience and Case Studies
Source: https://file.scirp.org/Html/12-1420477_79742.htm
Interesting excerpts:
... All patients were treated utilizing the Theralase TLC 900 series Low Level Laser.
... However, Theralase has developed a more efficacious system which will be more efficacious, due to
increased power for ATP activation.
Now I know the justification of your presence at this conference, back in Jan. 2017, to test the receptivity
of this technology:
Twitter: Theralase is present at the American Academy of Neurology’s Breakthroughs in Neurology
Conference, Jan 13-14, 2017, @ Sheraton Grand Phoenix, AZ
Also in line with Harvard's 2016 results:
Shining light on the head: Photobiomodulation for brain disorders
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066074/
that states this conclusion:
10. Conclusion
Many investigators believe that PBM for brain disorders will become one of the most important medical
applications of light therapy in the coming years and decades. Despite the efforts of “Big Pharma”,
prescription drugs for psychiatric disorders are not generally regarded very highly (either by the medical
profession or by the public), and many of these drugs perform little better than placebos in different trials,
and moreover can also have major side-effects [117]. Moreover it is well accepted that with the overall
aging of the general population, together with ever lengthening life spans, that dementia, Alzheimer's,
and Parkinson's diseases will become a global health problem [118], [119]. Even after many years of
research, no drug has yet been developed to benefit these neurodegenerative disorders. A similar state
of play exists with drugs for stroke (with the exception of clot-busting enzymes) and TBI. New indications
for tPBM such as global ischemia (brain damage after a heart attack), post-operative cognitive
dysfunction [120], and neurodevelopmental disorders such as autism spectrum disorder may well
emerge. Table 2 shows the wide range of brain disorders and diseases that may eventually be treated by
some kind of tPBM, whether that be an office/clinic based procedure or a home-use based device. If
inexpensive LED helmets can be developed and successfully marketed as home use devices, then we
are potentially in a position to benefit large numbers of patients (to say nothing of healthy individuals).
Certainly the advent of the Internet has made it much easier for knowledge about this kind of home
treatment to spread (almost by word of mouth so to speak).tment to spread (almost by word of mouth so
to speak).
From: bencro
Date: 2/5/2018 2:00:07 PM
Subject: Warrants ... Frost ...
The number of shares (126M) has not changed since a while. So I doubt this could be the explanation to
your post
From: bencro
Date: 11/29/2017 8:44:50 PM
Subject: TLT: Moved to North York
Thanks for your leadership on this board. Not enough people like you. And too many bashers and
whiners.
***** Please keep this for yourself, as TLT acted low profile on this *****
Last 3 years rents (as per SEDAR):
Rent:
2017: 74,039$
2016: 60,900$
2015: 60,900$
So a hike of +21.3% (+1094$/month). That's probably why they decided to look for another place and
found North York.
We can already see how much it will cost them in North York:
See p. 10 of the SEDAR document, note a):
2018: 57,504$
2019: 57,887$
2020: 59,797$
2021: 59,797$
2022: 49,831$
a) Lease obligations under a lease agreement related to the Company’s premises, commenced on
October 1, 11 2017 and expires on September 30, 2022. Under the terms of this lease, the Company is
required to pay a proportionate share of operating costs, realty taxes and utilities, in addition to the
minimum rental payments. The future minimum lease payments are shown in the table above.
So lower than in 2015 and 2016. And way lower than 2017.
So nice intelligent move, money wise.
From: bencro
Date: 11/9/2017 11:58:24 AM
Subject: Input from Roger
Good posts from you. Thanks for your intelligent contribution.
Just remember that those that sold yesterday in panic right at the opening without having been intelligent
enough to interpret the content of the press release are probably the same that were only talking about a
stock price, instead of mastering the environment in which they were investing in. The same clowns that
will then blame Roger for "dilution" later on!!! How pathetic can this be!
They're going into a Ph. 2 with this technology.
Input from Roger
******* Keep this for yourself please *******
1. It's solid good news. PMH Oncologists are happy with it.
2. Hopefully 5 more treated by Dec / Jan and then with 3 months data they can apply for PH2.
3. No JV until phase 2 results likely...
4. No interest from anyone to buy a piece of Theralase now.
5. More news to come.
6. PH2 can have multiple treatments and then the immunity will kick in.
7. These patients were gonna have their bladders taken out. This is a great result.
The press release was strong and indicates a new option (Theralase PDT) for patients suffering from
refractory NMIBC versus dying from the disease, if they choose not to have a radical cystectomy
(bladder removal) or they are not indicated for the surgery.
For those who sold, they simply locked in their losses versus waiting for a Phase 2 clinical study, which
moves us closer to commercialization.
Thanks,
Roger
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
more to come soon>>>